**List of Figures**

<table>
<thead>
<tr>
<th>Figure No.</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 2.1</td>
<td>Possible pathways for dermal delivery of drug</td>
<td>4</td>
</tr>
<tr>
<td>Figure 2.1</td>
<td>Anatomy of Skin</td>
<td>13</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>A schematic representation of the skin and the way various enhancement strategies</td>
<td>16</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td>Various techniques of optimizing transdermal drug delivery</td>
<td>20</td>
</tr>
<tr>
<td>Figure 2.4</td>
<td>O/W type, W/O type and bicontinuous microemulsion</td>
<td>27</td>
</tr>
<tr>
<td>Figure 2.5</td>
<td>Different regions of phase diagram</td>
<td>35</td>
</tr>
<tr>
<td>Figure 2.6</td>
<td>Ternary system</td>
<td>35</td>
</tr>
<tr>
<td>Figure 2.7</td>
<td>Immunological pathways in atopic dermatitis</td>
<td>49</td>
</tr>
<tr>
<td>Figure 2.8</td>
<td>Mechanism of action of topical corticosteroids</td>
<td>60</td>
</tr>
<tr>
<td>Figure 2.9</td>
<td>Methods for BA/BE testing of topical glucocorticoids</td>
<td>65</td>
</tr>
<tr>
<td>Figure 2.10</td>
<td>Mechanism of action of topical calcineurin inhibitors</td>
<td>69</td>
</tr>
<tr>
<td>Figure 3.1</td>
<td>UV spectra of halobetasol propionate (5-45 mcg/ml) in methanol</td>
<td>113</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>Calibration curve of halobetasol propionate in methanol at 239nm</td>
<td>113</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>Visible spectra of halobetasol propionate (2.5-12.5 mcg/ml) by tetrazolium blue colormetric method</td>
<td>116</td>
</tr>
<tr>
<td>Figure 3.4</td>
<td>Calibration plot of halobetasol propionate by tetrazolium blue method (525 nm)</td>
<td>116</td>
</tr>
<tr>
<td>Figure 3.5</td>
<td>Chromatogram of halobetasol propionate 10 mcg/ml</td>
<td>118</td>
</tr>
<tr>
<td>Figure 3.6</td>
<td>Calibration curve of halobetasol propionate by HPLC at 239 nm</td>
<td>118</td>
</tr>
<tr>
<td>Figure 3.7</td>
<td>Chromatograms of tacrolimus</td>
<td>120</td>
</tr>
<tr>
<td>Figure 3.8</td>
<td>Calibration curve of tacrolimus by HPLC at 210 nm</td>
<td>120</td>
</tr>
<tr>
<td>Figure 3.9</td>
<td>Chromatogram of tacrolimus (50 mcg/ml)</td>
<td>121</td>
</tr>
<tr>
<td>Figure 3.10</td>
<td>Calibration curve of tacrolimus by HPLC at 210 nm</td>
<td>122</td>
</tr>
<tr>
<td>Figure 3.11</td>
<td>Calibration plot of serum IgE levels in mice by ELISA</td>
<td>123</td>
</tr>
<tr>
<td>Figure 4.1</td>
<td>Phase diagram of HP system 1</td>
<td>140</td>
</tr>
<tr>
<td>Figure 4.2</td>
<td>Phase diagram of HP system 2</td>
<td>140</td>
</tr>
<tr>
<td>Figure 4.3</td>
<td>Phase diagram of HP system 3</td>
<td>141</td>
</tr>
<tr>
<td>Figure 4.4</td>
<td>Contour plot for zeta potential of HP system1</td>
<td>143</td>
</tr>
<tr>
<td>Figure 4.5</td>
<td>Contour plots for globule size of HP system 1</td>
<td>143</td>
</tr>
<tr>
<td>Figure 4.6</td>
<td>Contour plot for zeta potential of HP system2</td>
<td>146</td>
</tr>
<tr>
<td>Figure 4.7</td>
<td>Contour plot for globule size of HP system2</td>
<td>146</td>
</tr>
</tbody>
</table>
Figure 4.8  Contour plot for zeta potential of HP system 3 149
Figure 4.9  Contour plot for globule size of HP system 3 149
Figure 4.10 Zeta potential distribution of the optimized batch A14 151
Figure 4.11 Size distribution of the optimized batch A14 151
Figure 4.12 Phase diagram of Tac system 1 152
Figure 4.13 Phase diagram of Tac system 2 152
Figure 4.14 Phase diagram of Tac system 3 153
Figure 4.15 Contour plot for zeta potential of Tac system 1 155
Figure 4.16 Contour plot for globule size of Tac system 1 155
Figure 4.17 Contour plot for zeta potential of Tac system 2 158
Figure 4.18 Contour plot for globule size of Tac system 2 158
Figure 4.19 Contour plot for zeta potential of Tac system 3 161
Figure 4.20 Contour plot for globule size of Tac system 3 161
Figure 4.21 Zeta potential distribution of the optimized batch D12 163
Figure 4.22 Size distribution of the optimized batch D12 163
Figure 4.23 Transmission electron microscopic image of HP ME 164
Figure 4.24 Transmission electron microscopic image of Tac ME 164
Figure 4.25 TEM image of cetomacrogol cream base after negative staining with phosphotungstic acid 165
Figure 4.26 TEM image of cetomacrogol cream base after incorporation of HP ME and negative staining with phosphotungstic acid. 165
Figure 4.27 TEM image of cetomacrogol cream base after incorporation of Tac ME and negative staining with phosphotungstic acid. 166
Figure 5.1 A two compartment diffusion cell 183
Figure 5.2 Comparative cumulative HP release through semi permeable cellulose acetate membrane 193
Figure 5.3 Comparative HP retention in rat skin and human cadaver skin following 24 h application 193
Figure 5.4 Comparative cumulative Tac release through semi permeable cellulose acetate membrane 196
Figure 5.5 Comparative Tac retention in rat skin and human cadaver skin following 24 h application 196
Figure 6.1 HE staining of rat biopsy for placebo group 214
Figure 6.2 Toluidine Blue staining of rat biopsy for placebo group 214
Figure 6.3 HE staining of rat skin biopsy for HPMEC0.035% group 215
Figure 6.4 Toluidine Blue staining of rat skin biopsy for HPMEC 0.035% group. 215
HE staining of rat skin biopsy for HPMEC 0.05% group

Toluidine Blue staining of rat skin biopsy for HPMEC 0.05% group.

HE staining of rat skin biopsy for TacMEC 0.1% group

Toluidine Blue staining of rat skin biopsy for TacMEC 0.1% group

Irritation score in human subjects over a period of 48 hours

Conversion from a Th1- (left) to a Th2-dominated (right) response upon repeated hapten application in a hapten-induced mouse model

Penetration of 6-coumarin into mice abdominal skin from HP cream

Penetration of 6-coumarin into mice abdominal skin from HP ointment

Penetration of 6-coumarin into mice abdominal skin from HPMEC

Comparative dermatitis score in mice during the course of study after elicitation with inducing agent (TNCB) and treatment with different formulations

Ear swelling response in mice recorded 3 h post application of formulations

Ear swelling response in mice recorded 24 h post application of formulations

Comparative serum total IgE levels during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different HP formulations

Histopathology of ear skin lesions caused by repeated application of TNCB and after treatment with HP formulations in BALB/C mice

Mast cell numbers during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different formulations

Gel electrophoresis of total RNA extracted from mice ear

Cytokine mRNA expression in the skin lesion excised 24 h after elicitation with TNCB painting

Cytokine gene expression by RT-PCR at the end of study on day 35
Figure 7.14 Penetration of 6-coumarin into mice abdominal skin from Tac ointment
Figure 7.15 Penetration of 6-coumarin into mice abdominal skin from Tac MEC
Figure 7.16 Comparative dermatitis score in mice during the course of study after elicitation with inducing agent (TNCB) and treatment with different Tac formulations
Figure 7.17 Comparative serum total IgE levels during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different Tac formulations
Figure 7.18 Ear swelling response in mice recorded 3 h post application of formulations
Figure 7.19 Ear swelling response in mice recorded 24 h post application of formulations
Figure 7.20 Mast cell numbers during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different Tac formulations
Figure 7.21 Histopathology of ear skin lesions caused by repeated application of TNCB and treatment with different Tac formulations in BALB/C mice
Figure 7.22 Cytokine mRNA expression in the skin lesion excised 24 h after elicitation with TNCB painting
Figure 7.23 Cytokine gene expression levels by RT-PCR at the end of study on day 35.
Figure 8.1 Skin blanching curve for HP cream 0.05% and HPMEC 0.035% after 2 h of application
Figure 8.2 Skin blanching curve for HP cream 0.05% and HPMEC 0.035% after 4 h of application
Figure 8.3 Skin blanching curve for HP cream 0.05% and HPMEC 0.035% after 6 h of application
Figure 8.4 Comparative percentage reduction in signs and symptoms at the end of treatment for HPMEC 0.035% and HP cream 0.05%
Figure 8.5 Comparative percentage reduction in signs and symptoms at the end of treatment for HPMEC 0.035% and MEC placebo
Figure 8.6 Comparative percentage reduction in signs and symptoms at the end of treatment for HP cream 0.05% and Cream Placebo
Figure 8.7  Comparative percentage reduction in signs and symptoms at the end of treatment for MEC Placebo and Cream Placebo

Figure 8.8  Comparative overview of patient & physician global assessment for group1: HPMEC 0.035% and group2: HP Cream 0.05%

Figure 9.1  Chromatogram of HP at 239 nm
Figure 9.2  Chromatogram of Tac at 210 nm

Figure 9.3  DSC thermograms a) Tacrolimus b) Halobetasol propionate

Figure 9.4  DSC thermograms a) Tac + HP mix at time 0. b) Tac + HP mix at time 1 month

Figure 9.5  Comparative cumulative drug release through semi permeable cellulose acetate membrane

Figure 9.6  Comparative drug retention in rat skin and human cadaver skin following 24 h application

Figure 9.7  Comparative dermatitis score in mice during the course of study after elicitation with inducing agent (TNCB) and treatment with different formulations

Figure 9.8  Comparative serum total IgE levels during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different formulations.

Figure 9.9  Ear swelling response in mice recorded 3 h post application of formulations

Figure 9.10  Ear swelling response in mice recorded 24 h post application of formulations

Figure 9.11  Histopathology of ear skin lesions caused by repeated application of TNCB and after treatment with formulations in BALB/C mice

Figure 9.12  Cytokine gene expression levels by RT-PCR at the end of study on day 35